GlassScriptPhysician profile
Jordan Brotz
NPI 1104574334
$1,033.15
in general payments reported to CMS, 2019-2025
17 companies · $735 in 2025
The $735 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $36.44 · 2024: $262 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $234.43 | 2024-2025 | Rexulti |
| Alkermes, INC. | $193.89 | 2025 | Aristada, Lybalvi, Aristada Initio |
| Astrazeneca Pharmaceuticals LP | $97.64 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $78.61 | 2024-2025 | Ozempic, Rybelsus |
| Lundbeck LLC | $66.01 | 2025 | Rexulti |
| Grifols USA, LLC | $57.90 | 2024-2025 | Prolastin-C Liquid |
| Sumitomo Pharma America, INC. | $53.74 | 2023-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $43.30 | 2025 | Invega Sustenna |
| Dexcom, INC. | $35.55 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $33.21 | 2024-2025 | Trelegy Ellipta |
| Neurocrine Biosciences, INC. | $25.57 | 2025 | |
| Daiichi Sankyo INC. | $24.61 | 2024 | Injectafer |
| Phathom Pharmaceuticals, INC. | $21.29 | 2025 | Voquezna |
| Radius Health, INC. | $19.03 | 2024 | Tymlos |
| Philips North America LLC | $17.33 | 2025 | Vest Therapy Und |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $16.70 | 2025 | Uzedy |
| Averitas Pharma INC. | $14.34 | 2025 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Brotz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.